In our study, we observed that decreased Notch1 activity in luminal-type MCF7 cells results in the increased sensitivity of these cells for CDDP treatment, proving that measuring the prognostic value of Notch1 expression can help to guide individual therapy for BC patients [18]. This evidence concerns the gene NOTCH1 and breast cancer.